消乳块胶囊对乳腺肿瘤模型大鼠血浆IGF-1水平的影响

Effect of "Xiao Rukuai" Capsule on Plasma Insulin-like Growth Factor-1 in Rats with Mammary Tumor

目的观察消乳块胶囊对乳腺肿瘤模型大鼠血浆胰岛素样生长因子-1(IGF-1)水平的影响。方法 64只50日龄SD健康雌性未孕大鼠随机分为模型组、治疗组各25只和对照组14只。模型组和治疗组大鼠均先经2次9,10-二甲基苯蒽(DMBA,15mg溶于1.5m L芝麻油,间隔1周)灌胃造模,同时治疗组大鼠以消乳块胶囊0.4g/(kg·d)灌胃,持续给药,在第11周和14周分批处死大鼠,取乳腺组织及肿瘤组织作常规病理检查,酶联免疫吸附法测定血浆IGF-1水平。结果与病理表现正常大鼠相比,乳腺癌变及增生大鼠血浆IGF-1水平升高明显[(138.65±8.54)ng/m L、(212.32±10.38)ng/m L比(97.70±5.16)ng/m L,P<0.01],癌变大鼠增高更为明显,与增生大鼠相比,差异有统计学意义[(212.32±10.38)ng/m L比(138.65±8.54)ng/m L,P<0.05]。模型组、治疗组11、14周时血浆IGF-1较对照组明显增高[11周:(196.99±7.85)ng/m L、(142.33±8.62)ng/m L比(101.46±7.07)ng/m L,P<0.01;14周:(229.40±13.37)ng/m L、(138.75±8.82)ng/m L比(90.26±2.50)ng/m L,P<0.01],治疗组11、14周血浆IGF-1水平较模型组有明显下降[11周:(142.23±8.62)ng/m L比(196.99±7.85)ng/m L,P<0.01;14周:(138.75±8.82)ng/m L比(229.40±13.37)ng/m L,P<0.01]。结论消乳块胶囊对DMBA诱导的大鼠乳腺恶性肿瘤具有部分预防作用,其机制可能是通过降低血浆IGF-1水平来实现。

Objective To investigate the anticancer effect of ＂Xiao Rukuai＂ capsule on plasma insulin-like growth factor-1 （IGF-1） in rats with mammary tumor. Methods Sixty-four 50-day-old female Sprague-Dawley rats were randomly divided into 3 groups： model group （n=25）, therapy group （n=25）, and control group （n=14）. Model group and therapy group were given DMBA by intragastric administration （15mg in 1.5mL sesame oil, twice, one week in-terval）. Rats in therapy group were given additonal ＂Xiao Rukuai＂ capsule [0.4g/（kg·d）]by intragastric administration. All rats were killed in 11th or 14th week. The breast tissue or neoplasma were observed by routine pathology. The plasma IGF-1 levels were detected by ELISA assay. Results Compared to normal group, the levels of IGF-1 were remarkably higher in the cancerous and hyperplastic group （138.65±8.54ng/mL and 212.32±10.38ng/mL vs 97.70±5.16ng/mL, P〈0.01）; a significant difference was found between cancerous group and hyperplasia group （212.32±10.38ng/mL vs 138.65±8.54ng/mL, P〈0.01）. At 11th and 14th week, the levels of IGF-1 in the plasma in model and therapy group were significantly higher than that in control group （at 11th week： 196.99±7.85ng/mL and 142.33±8.62ng/mL vs 101.46±7.07ng/mL; at 14th week： 229.40±13.37ng/mL and 138.75±8.82ng/mL vs 90.26±2.50ng/mL; all P〈0.01）. After ＂Xiao Rukuai＂ capsule treatment, the levels of IGF-1 reduced remarkably, with a significant difference compared to that in model group （at 11th week： 142.33±8.62ng/mL vs 196.99±7.85ng/mL; at 14th week： 138.75±8.82ng/mL vs 229.40±13.37ng/mL; all P〈0.01）. Conclusion The ＂Xiao Rukuai＂ capsule has partly effect on prevent-ing the mammary carcinogenesis induced by DMBA. The mechanism may be associated with regulating IGF-1 levels.